Alto Neuroscience (ANRO)

• Market cap: $859M
• 1 day: -4.63%
• 5 days: -11.13%
• 1 month: 21.45%
• 3 months: 49.42%
• 6 months: 122.91%
• Year to date: 47.8%
• 1 year: 975.44%
• 5 years: 18.45%
• 10 years: 18.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 68